Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

only, which includes the colon and the rectum. The most common symptoms of UC include abdominal discomfort and blood or pus in diarrhea. There is no known cause for CD or UC, although many researchers believe that the interaction between genes, the body's immune system, and environmental factors may play a role. The aim of CD and UC treatments is to induce and maintain remission, or achieve extended periods of time when patients do not experience symptoms.

About vedolizumab
Vedolizumab, under development for the treatment of CD and UC, is a humanized monoclonal antibody that specifically antagonizes the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1). MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract. The alpha4beta7 integrin is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in CD and UC. 

About Takeda Pharmaceuticals U.S.A., Inc.
Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

The company has a commercial presence covering around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Areas of focus include cardiovascular and metabolic, oncology, respiratory and immunology, central nervou
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- This is a professional ... Heparin sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) ... of Heparin sodium (CAS 9041-08-1) & calcium (CAS ... The report then explores global and China,s top ... (CAS 37270-89-6) listing their product specification, capacity, production ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
(Date:7/30/2014)... California , July 30, 2014 ... technology and CUDA programming expertise to big data, ... markets  eInfochips, a leading engineering R&D ... clients to develop NVIDIA GPU-powered solutions for ... high-performance computing (HPC), industrial , ...
Breaking Medicine Technology:Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... Reportlinker.com announces that a new market research ... Pharmaceuticals: Global Industry Guide ... Pharmaceuticals: Global Industry Guide is ... analysis covering the Pharmaceuticals industry. It includes ...
... 2012 Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE ... three lead drugs (Zertane™ completed two phase ... licensing distribution of these drugs and engaged in further ... interim review of the first 50% of patients enrolled ...
Cached Medicine Technology:Pharmaceuticals: Global Industry Guide 2Pharmaceuticals: Global Industry Guide 3Pharmaceuticals: Global Industry Guide 4Pharmaceuticals: Global Industry Guide 5Pharmaceuticals: Global Industry Guide 6Pharmaceuticals: Global Industry Guide 7Pharmaceuticals: Global Industry Guide 8Pharmaceuticals: Global Industry Guide 9Pharmaceuticals: Global Industry Guide 10Pharmaceuticals: Global Industry Guide 11Pharmaceuticals: Global Industry Guide 12Pharmaceuticals: Global Industry Guide 13Pharmaceuticals: Global Industry Guide 14Pharmaceuticals: Global Industry Guide 15Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 2Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 3Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 4
(Date:7/30/2014)... Rancho Cucamonga, CA (PRWEB) July 30, 2014 ... career learning how to make millions. However, like most people, ... all. Determined to find a better way, Paul carefully ... lasting wealth and those who do not. Based on the ... learned to not only improve his life and health, but ...
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... July 30, 2014 Good Neighbor ... in an upcoming episode of Innovations with Ed ... Channel. Dates and show times TBA. , In ... Neighbor Community Services’ vision to redefine the traditional ... and dynamic services. Through passion, innovation, determination, excellence, ...
(Date:7/30/2014)... -- It can happen in an instant: A small child ... and gets critically injured when the furniture tips over. ... around their homes and imagine what could tip over, fall ... than it becoming a reality," Dr. Alex Rosenau, president of ... news release. Between 2009 and 2011, roughly 43,000 people ...
(Date:7/30/2014)... cancer as well as evolutionary changes in a living ... randomly throughout the genome. , However, recent studies have ... multiple mutations that arise simultaneously and in close proximity ... frequently found in regions where chromosomal rearrangements take place. ... Reports , may one day lead to new cancer ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2
... macular degeneration, also called juvenile macular degeneration, is an ... This condition results from a defect in the ABCR ... that removes all-trans-retinaldehyde, a vision byproduct, from retinal rods ... epithelium (RPE), a layer of cells near the retina. ...
... inflammatory condition of the bladder wall. It typically affects ... men. Investigators are testing the bacteria Bacillus Calmette-Guerin(BCG), which ... treating interstitial cystitis, by inserting six installations into the ... study of BCG// also showed that 60 percent of ...
... a screening of the colon do not go through ... procedure that is currently available involves inserting a flexible ... requires anaesthesia and there's a remote chance that the ... patients now have an easier option with the discovery ...
... worldwide and its incidence is high in the Asian and ... foodstuffs. The cancer is also becoming prevalent in the United ... gene activity in liver tumors using the new 'gene chip' ... They found that there is a difference between// those tumors ...
... has shown that infants born during night time have ... to those born during day time. Previous studies have ... weekends and holidays have an increased risk of death ... experienced staff for better obstetric and neonatal care during ...
... Vitamin C has been believed, over the years, to be a ... proved to be true by researchers who have studied changes in ... their study of 12 healthy subjects who took one gram of ... immune system response in all of them during the period. Their ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: